|
Jun 26
|
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
|
|
May 6
|
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
|
|
Feb 12
|
Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference
|
|
Oct 9
|
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
|
|
Jul 25
|
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
|
|
Dec 19
|
Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
|
|
Dec 18
|
Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
|
|
Aug 7
|
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
|